Eos

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Concinnity Genetics specializes in enhancing the safety of gene therapies. It employs an artificial intelligence platform to engineer innovative control mechanisms, making gene therapies more predictable, controllable, and safe. This enables researchers to swiftly design and optimize gene therapies for diverse applications.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Naturbeads Ltd., established in 2018 and headquartered in Malmesbury, UK, specializes in manufacturing biodegradable cellulose microparticles. These products aim to replace conventional plastic microbeads used in cosmetics, toiletries, and other industries. The company's mission is to mitigate microplastic pollution by offering a sustainable alternative developed through innovative research at the University of Bath.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, specializing in the development, manufacturing, and distribution of wavelength tunable femtosecond lasers. Founded as a spin-out from Heriot-Watt University in 2013, it boasts a founding team with over 40 years of experience in ultrafast lasers. Chromacity's product lineup includes several advanced lasers such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, designed for life sciences and spectroscopy applications. The company also offers Spark-X and Spark-OPO models, which provide tunable femtosecond pulses across various wavelengths for applications in two-photon stimulation and spectroscopy, respectively. Their robust, patent-pending fiber-laser technology ensures reliable performance, complemented by a user-friendly web-based interface for easy operation. In addition to standard products, Chromacity collaborates with systems manufacturers to create custom OEM femtosecond and picosecond lasers tailored for specific engineering and materials processing needs. The company serves a global customer base across North America, the UK, and the Middle East.

Nami Surgical specializes in developing and providing advanced robotic surgery technology. Their core offering is ultrasonic surgical tools designed to enhance the current robotic-assisted surgery market. By simplifying and making procedures safer, they expand the use of robots in surgeries requiring ultrasonic devices, thereby improving clinical outcomes and patient care. Their solutions provide surgeons with intuitive, high-performance, and maneuverable instruments for complex surgical tasks.

Neupulse, operating under Neurotherapeutics Ltd, is dedicated to developing non-drug treatments for individuals with tic disorders, including Tourette Syndrome. The company focuses on peripheral nerve stimulation to influence brain networks related to tic production. Responding to feedback from patients and families, Neupulse has created a wearable device that resembles a wristwatch, which delivers rhythmic patterns of mild electrical stimulation to the median nerve at the wrist. This innovative approach has been shown to significantly reduce tic frequency and alleviate the urge to tic without adversely affecting intentional movements or cognitive functions. By providing users with a tool to monitor and manage their condition outside clinical settings, Neupulse aims to empower individuals to regain control over their tics and improve their overall quality of life.

Wobble Genomics is a biotechnology firm focused on the discovery and detection of nucleic acid biomarkers, utilizing advanced RNA and DNA sequencing techniques. The company aims to achieve unprecedented sensitivity and accuracy in biomarker identification by integrating biochemistry with bioinformatics. This innovative approach enhances sequencing efficiency, allowing medical researchers to optimize sampling processes while reducing costs. By streamlining the discovery of nucleic acid biomarkers, Wobble Genomics contributes to advancements in medical research and diagnostics.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

Laverock Therapeutics is focused on advancing a gene silencing platform that facilitates the development of programmable, allogeneic cell therapies. This innovative platform allows for the engineering of next-generation cell therapies that are both adaptive and capable of responding to various intra- and extra-cellular environmental cues. By enhancing the functionality of these therapies, Laverock Therapeutics aims to improve the efficacy, safety, and accessibility of iPSC-derived products, addressing significant limitations associated with current therapeutic approaches. The company's work is positioned to benefit medical and biotechnology institutions seeking to leverage advanced cell therapy solutions.

Chemify specializes in developing a chemical digitization platform designed to facilitate drug and materials discovery as well as chemical synthesis. The company's innovative approach involves using automated synthetic hardware combined with digital XDL code to convert code into molecules on demand. This system is modular, universal, scalable, and teachable, making it highly versatile for various applications in chemical and material research. Chemify's software includes a unique chemical programming language and natural language recognition capabilities that translate synthetic procedures efficiently. Additionally, the platform features a comprehensive ontology that provides detailed insights into reaction conditions and flags potential issues, offering scientists real-time telemetry of reactions.

Bioliberty is a medtech startup focused on developing innovative rehabilitation solutions for individuals with degenerative and traumatic conditions. The company specializes in creating robotic gloves that leverage artificial intelligence to aid muscle recovery. By utilizing assistive robotics and rehabilitative devices, Bioliberty aims to support patients suffering from various ailments, including stroke, motor neuron disease, multiple sclerosis, rheumatoid arthritis, and osteoarthritis. These solutions are designed to address hand weakness, empowering users to perform daily tasks and enhance their hand strength, ultimately enabling them to live more comfortably and independently in their own homes.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Waire Health is a developer of wearable vital sign monitoring devices aimed at enhancing patient care in hospitals and home settings. The company's technology continuously monitors vital signs and utilizes advanced artificial intelligence to identify patterns that may indicate the onset of critical conditions, such as sepsis, before they escalate to life-threatening levels. By providing real-time data, Waire Health enables clinicians to make informed decisions and facilitate timely interventions for high-risk patients. This approach not only helps reduce healthcare costs but also contributes to improved patient outcomes by ensuring that individuals receive the necessary attention and care when needed.

Green Bioactives is a company focused on sustainable plant cell-based biomanufacturing, leveraging natural plant biochemistry to produce bioactive molecules. The company has developed a platform that identifies, isolates, and cultivates plant vascular stem cells for various commercial applications. This innovative approach allows for the creation of new options aimed at enhancing food production on an industrial scale. Green Bioactives serves multiple markets, including cosmetics, pharmaceuticals, food, and agriculture, by providing novel solutions that address the global demand for sustainable and efficient food production.

Penrhos Bio is a bioscience company focused on developing innovative, organically inspired substances aimed at addressing bacterial and microbial biofilm challenges. Its platform provides sustainable, low-toxicity alternatives to traditional biocides by utilizing molecules that disrupt quorum sensing and communication among bacteria. This approach enables Penrhos Bio to offer effective solutions for microbial contamination across various sectors, including marine, textile, paper, household cleaning, and healthcare industries. Through its unique technology, the company seeks to enhance safety and efficacy in managing microbial issues, contributing to improved outcomes in diverse environments.

RAB Microfluidics specializes in diagnosing early signs of failure in lubricated machinery by utilizing its patented microfluidic technology and artificial intelligence. The company has developed a lab-on-a-chip solution that automates the analysis of lubricating oil, enabling real-time data delivery that identifies equipment deterioration and impending failures. This innovative approach revolutionizes maintenance practices across various industries, including maritime, renewable energy, aerospace, and manufacturing. By providing laboratory-quality data and actionable insights, RAB Microfluidics aims to enhance equipment reliability and effectiveness, facilitating a shift towards Condition-based Maintenance (CbM) and Predictive Maintenance (PdM) strategies. The company's mission is to empower businesses with intelligent insights into machinery conditions, ultimately reducing costs and improving operational efficiency.

Naturbeads Ltd., established in 2018 and headquartered in Malmesbury, UK, specializes in manufacturing biodegradable cellulose microparticles. These products aim to replace conventional plastic microbeads used in cosmetics, toiletries, and other industries. The company's mission is to mitigate microplastic pollution by offering a sustainable alternative developed through innovative research at the University of Bath.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

Wobble Genomics is a biotechnology firm focused on the discovery and detection of nucleic acid biomarkers, utilizing advanced RNA and DNA sequencing techniques. The company aims to achieve unprecedented sensitivity and accuracy in biomarker identification by integrating biochemistry with bioinformatics. This innovative approach enhances sequencing efficiency, allowing medical researchers to optimize sampling processes while reducing costs. By streamlining the discovery of nucleic acid biomarkers, Wobble Genomics contributes to advancements in medical research and diagnostics.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

RAB Microfluidics specializes in diagnosing early signs of failure in lubricated machinery by utilizing its patented microfluidic technology and artificial intelligence. The company has developed a lab-on-a-chip solution that automates the analysis of lubricating oil, enabling real-time data delivery that identifies equipment deterioration and impending failures. This innovative approach revolutionizes maintenance practices across various industries, including maritime, renewable energy, aerospace, and manufacturing. By providing laboratory-quality data and actionable insights, RAB Microfluidics aims to enhance equipment reliability and effectiveness, facilitating a shift towards Condition-based Maintenance (CbM) and Predictive Maintenance (PdM) strategies. The company's mission is to empower businesses with intelligent insights into machinery conditions, ultimately reducing costs and improving operational efficiency.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

GM Flow specializes in providing flow measurement services and products tailored for the oil and gas industry. The company develops advanced gas flow measurement equipment that includes features such as data logging capabilities, battery power, and wireless options. These innovations allow operators to accurately monitor flow and pressure rates, even in challenging oilfield environments. By focusing on precision and reliability, GM Flow aims to enhance the efficiency and safety of energy measurement processes within the sector.

Rooser is a business-to-business cloud-based platform located in Edinburgh, Scotland, that facilitates seafood trade across Europe. The platform connects seafood buyers and suppliers, providing them with tools to streamline the trading process, negotiate prices, and manage deliveries efficiently. By offering an online marketplace specifically for fresh fish, Rooser aims to simplify fish commerce for established seafood businesses, enhancing their ability to connect and transact effectively.